Research quantifies growth in immuno-oncology combination trials

A new report looking at the booming market for immuno-oncology treatments has quantified the rise in clinical trials using PD-1 and PD-L1 antibodies, combined with other therapeutic approaches.

These therapies seek to interrupt a biochemical shield created when a tumor combines a protein called programmed death ligand-1 (PD-L1) with another found in the body’s immune system, called programmed death-1 (PD-1).

The report from EP Vantage finds that, as of April 2017, there were 765 studies of this type, an increase from the 215 found in November 2015.